Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DROGLICAN in Knee Osteoarthritis
NCT02821468Phase 4Unknown
- Sponsor
- Bioiberica
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Droglican in osteoarthritis (OA) (2 arms), sponsored by Bioiberica. Primary endpoint: Change of composition of cartilage trough imaging marker (dGEMRIC) at 6 months. Status: unknown.
02
Drugs
Droglican
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02821468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821468.